Skip to main content

Table 2 Association between MALAT1 expression and overall survival

From: Clinicopathological and prognostic significance of long noncoding RNA MALAT1 in human cancers: a review and meta-analysis

Survival analysis Subgroup Studies (n) Patients (n) HR (95% CI) P Heterogeneity (I2, P)
Univariate Overall 15 1869 2.296 (1.716–3.072) 0.000 67.6%, 0.000
Region
China 12 1209 2.793 (2.310–3.376) 0.000 0.0%, 0.924
Other 3 660 1.164 (0.577–2.346) 0.672 83.5%, 0.002
Cancer type
Estrogen-dependent carcinoma 2 198 3.296 (2.027–5.358) 0.000 22.9%, 0.255
Urological carcinoma 2 226 3.184 (2.072–4.892) 0.000 0.0%, 0.739
Glioma 2 258 2.750 (1.839–4.111) 0.000 0.0%, 0.553
Digestive carcinoma 6 633 1.750 (0.974–3.143) 0.061 79.7%, 0.000
Other 3 554 2.154 (1.471–3.154) 0.000 0.0%, 0.484
Sample size
Sample < 100 5 333 2.443 (1.655–3.608) 0.000 0.0%, 0.752
Sample > 100 10 1536 2.203 (1.516–3.202 0.000 77.9%, 0.000
Multivariate Overall 18 1891 2.298 (1.953–2.704) 0.000 17.2%, 0.248
Region
China 17 1817 2.327 (1.968–2.751) 0.000 20.6%, 0.213
Other 1 74 1.880 (0.957–3.695) 0.067
Cancer type
Estrogen-dependent carcinoma 2 198 2.656 (1.560–4.523) 0.000 0.0%, 0.457
Urological carcinoma 3 321 1.952 (1.189–3.204) 0.008 51.4%, 0.128
Glioma 4 430 2.315 (1.643–3.263) 0.000 0.0%, 0.534
Digestive carcinoma 7 706 2.451 (1.862–3.227) 0.000 45.4%, 0.089
Other 2 236 2.383 (1.449–3.920) 0.001 3.3%, 0.309
Sample size
Sample < 100 7 528 2.017 (1.520–2.677) 0.000 10.4%, 0.350
Sample > 100 11 1363 2.451 (2.009–2.990) 0.000 20.7%, 0.246
  1. If I2 > 50%, the results were calculated by random model
  2. HR hazard ratio, CI confidence interval